These data indicate that HGF reduced sensitivity to gefitinib by restoring MET-mediated phosphorylation of Akt and ERK1/2 in cells harboring wild-type EGFR, consistent with previous data examining EGFR mutant lung cancer cells. The gene discussed is MAPK3; the disease is lung carcinoma.